Abstract: The present disclosure promotes distribution of sensor data among a plurality of business operators. A controller that an information processing system according to the present disclosure includes collects first data including a plurality of items and personal information from mobile bodies belonging to a first business operator. The controller converts the first data to second data not being usable to identify individuals. The controller provides data in a range decided based on content of a predetermined data use contract, among the second data, to a second business operator. The controller calculates a consideration for the data that is to be paid by the second business operator, based on a data use record of the second business operator.

Abstract: The present invention relates to an anti-SARS-CoV-2 drug including, as an active ingredient, a compound represented by formula (I): [wherein R1 is C1-C8 alkyl or the like; and R2-R9 is hydrogen, halogen, hydroxyl, or Q-(C1-C8 alkyl), (Q is O, NH, or S) or the like], or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to an agent for killing HIV-1-infected cells, comprising a compound represented by formula (I): wherein Ar1 and Ar2 are the same or different and represent a substituted or unsubstituted aromatic group, and X represents —CH2O— or —CH?CH—, its salt, or their solvate, and a combined preparation for simultaneous, separate, or sequential administration in treating or preventing HIV-1 infection, comprising two separate preparations: (a) a preparation comprising a compound represented by the formula (I), its salt, or their solvate, and (b) a preparation comprising an anti-HIV-1 drug.

Abstract: The present invention relates to an agent for killing HIV-1-infected cells, comprising a compound represented by formula (I): wherein Ar1 and Ar2 are the same or different and represent a substituted or unsubstituted aromatic group, and X represents —CH2O— or —CH?CH—, its salt, or their solvate, and a combined preparation for simultaneous, separate, or sequential administration in treating or preventing HIV-1 infection, comprising two separate preparations: (a) a preparation comprising a compound represented by the formula (I), its salt, or their solvate, and (b) a preparation comprising an anti-HIV-1 drug.

Abstract: Disclosed is a method used thereof for detecting HIV-1 in a saliva sample at early stages of viral infection. The method comprises the steps of: (A) providing glycan immobilized metal nanoparticles which can recognize HIV-1 and diluting the saliva sample to half of the concentration; (B) contacting the glycan immobilized metal nanoparticles with the saliva sample and a mixture is obtained, wherein a volume ratio of the glycan immobilized metal nanoparticles to the saliva sample is 1:49, wherein the HIV-1 in the saliva sample is approximately 0.1 to 10 copies/ml; (C) concentrating the mixture; and (D) determining HIV-1 in the concentrated mixture by a detecting method; wherein each of the glycan immobilized metal nanoparticles includes a ligand-conjugate, the ligand-conjugate has a linker compound, the linker compound has a formula (1).

Abstract: Disclosed are glycan immobilized metal nanoparticles and a method used thereof for detecting HIV-1 in a saliva sample at early stages of viral infection. The method comprises the steps of: (A) providing glycan immobilized metal nanoparticles which can recognize HIV-1; (B) contacting the glycan immobilized metal nanoparticles with the saliva sample and a mixture is obtained; (C) concentrating the mixture; and (D) determining HIV-1 in the concentrated mixture by an appropriate detecting method.